drugset / Trial / NCT00482521
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
Phase 1
Completed
42 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-09
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | — | Oral |